A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA
Phase of Trial: Phase III
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Eculizumab (Primary)
- Indications Neuromyelitis optica
- Focus Adverse reactions
- Acronyms PREVENT
- Sponsors Alexion Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 19 Nov 2016 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 10 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.